Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy. - Wikidata - wikimedia - TriplyDB

Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy.

Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy.

http://www.wikidata.org/entity/Q34528225

about

Prognostic and predictive biomarkers in prostate cancer: latest evidence and clinical implications.A novel nonsense mutation in androgen receptor confers resistance to CYP17 inhibitor treatment in prostate cancer Exploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapy-naïve castration-resistant prostate cancer: The Kyoto-Baltimore collaboration.Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-Resistant Prostate Cancer.Androgen Receptor Rearrangement and Splicing Variants in Resistance to Endocrine Therapies in Prostate Cancer.Androgen Signaling in Prostate Cancer.Rationale for the development of alternative forms of androgen deprivation therapy.HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study.A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer Association of Tissue Abiraterone Levels and SLCO Genotype with Intraprostatic Steroids and Pathologic Response in Men with High-Risk Localized Prostate Cancer.HSD3B1 and Response to a Nonsteroidal CYP17A1 Inhibitor in Castration-Resistant Prostate Cancer.Degarelix treatment is compatible with diabetes and antithrombotic therapy in patients with prostate cancer.HSD3B1 status as a biomarker of androgen deprivation resistance and implications for prostate cancer.Androgenic to oestrogenic switch in the human adult prostate gland is regulated by epigenetic silencing of steroid 5α-reductase 2.The Microwell-mesh: A high-throughput 3D prostate cancer spheroid and drug-testing platform.Loss of an Androgen-Inactivating and Isoform-Specific HSD17B4 Splice Form Enables Emergence of Castration-Resistant Prostate Cancer.Abiraterone acetate withdrawal syndrome: Speculations on the underlying mechanisms.Steroidogenic Metabolism of Galeterone Reveals a Diversity of Biochemical Activities.Efficacy and safety of different interventions in castration resistant prostate cancer progressing after docetaxel-based chemotherapy: Bayesian network analysis of randomized controlled trials.Using high throughput microtissue culture to study the difference in prostate cancer cell behavior and drug response in 2D and 3D co-cultures.Mechanism of the Dual Activities of Human CYP17A1 and Binding to Anti-Prostate Cancer Drug Abiraterone Revealed by a Novel V366M Mutation Causing 17,20 Lyase Deficiency.Dual Inhibitors of PARPs and ROCKs Inhibition of histamine receptor H3R suppresses prostate cancer growth, invasion and increases apoptosis via the AR pathway

P2860

Q38644658-43CA0250-C003-4C79-ADAD-FBE99FB34E41 Q38723579-E120F480-A118-4355-BC68-18EB1A00F563 Q38813222-AA0C966D-4EF9-4BAE-89C4-4564D718C26D Q38836163-2D57B76B-AB38-4E1B-9D8B-8AB8BA36C5B6 Q39215035-7E300B56-6537-4FA8-9108-356B9397CC7A Q39227656-96E00E8D-5BB2-4A04-93B3-BC688151B201 Q39342369-E617C1B6-5B1A-4F36-A7A6-571D78D1BA1B Q39440957-D2E70DE2-EE43-4E4C-A371-5C217E35AC9C Q42174990-AA4E050A-5215-4302-A97A-ED25EFFFD1FE Q45988129-0551998D-EC56-4FD6-82B7-93DFD0294322 Q46127807-EBAB8CE1-D807-4CBC-AF2A-C0E6954B0B2F Q47148733-1DB671BD-FAE6-4FAA-AFCA-89A024808221 Q47303485-2BB1F2D9-68AC-4D13-9BD0-B327D57111B7 Q47756626-460A7086-96BD-4D8F-B244-16EEE7A5527F Q49697990-1155A839-3D9C-4B78-B3A3-DBEEB9768CBB Q49817073-EBD85C01-C492-4227-9000-D61657154ED0 Q50053418-0CEB8CCE-D18C-4128-9B2E-9D0EF3E3A6DA Q50925353-6FF392E2-4794-4103-948F-0D1BFA455764 Q53700821-2A41C8C6-A497-4A0D-B04B-D567076E004D Q55317401-F5884077-4C91-4131-B8DB-67071BC13174 Q55638445-9308B0A2-8E23-4DF2-98CD-9EA0F9F50839 Q58581240-D4B69AB2-D09F-444A-8E58-34AF4DA93F4A Q58772565-7D4385AC-1C95-49E7-ADC9-34B958C7292C

P2860

Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy.

http://www.wikidata.org/entity/Q34528225

description

2016 nî lūn-bûn

@nan

2016 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy.

@ast

Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy.

@en

Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy.

@nl

type

label

Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy.

@ast

Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy.

@en

Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy.

@nl

prefLabel

Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy.

@ast

Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy.

@en

Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy.

@nl

P1433

Q34528225-CB9E1086-6B16-4533-8818-DD6EA31D4A2B

P1476

Q34528225-2816F30B-F386-42C0-A1B0-9D0234EA72B2

P2093

Q34528225-0743551A-D2FE-41B0-92BA-4AD91545C232

Q34528225-19CCCCA7-617A-4FA7-BC39-332C4A2AE27E

Q34528225-4C226C41-1135-4165-B64F-679D65B48B7C

Q34528225-B36437A4-6807-4D2A-A69A-CAC2C18E4B32

Q34528225-B3F577C9-7188-4BF0-8955-7BC0A779B38D

Q34528225-BA26669C-02AF-4FEF-8458-3CE3181EF0A7

Q34528225-D4F76CF2-21A3-4CE3-8B5B-D1B6B4CBE497

Q34528225-DE887677-E0CD-4651-A0F4-5543B6E98B34

Q34528225-E87EDFF8-FA7B-47CD-9E8D-FA5C9B81451C

P2860

Q34528225-0DF8FF11-30A7-4D21-B5F2-7EEB248F0B21

Q34528225-1C09194A-CC4E-441B-B2B1-4AFE31453AEE

Q34528225-1CE80D53-9821-43A9-8591-2CC800817ABB

Q34528225-3BC21F0F-B693-428E-B63E-A0A502B71369

Q34528225-443AC2C4-C071-49C8-BEDA-46622E386799

Q34528225-49485068-B243-499A-A61B-B750002EC0FE

Q34528225-4E69849B-B610-49DB-8054-C2297F6BB199

Q34528225-60BB91E2-3105-4316-89C7-43C66A171C17

Q34528225-696CBA90-F9AB-4350-8C75-4B94873971A2

Q34528225-697DAD37-91FF-4BF2-B838-B256A37BAF5E

P2888

Q34528225-FB48AA13-5033-4255-9FDC-5A7CA09E4181

P304

Q34528225-67C6FE5E-6886-4C42-BD66-BD83B64871CD

P31

Q34528225-B784A6A0-5847-4B72-93F7-A847E3040084

P356

Q34528225-FBD49B95-69D8-48C7-9E0D-BF9BE89FCA19

P407

Q34528225-DF8BA1E5-F911-43DE-A148-D7AFF091044A

P433

Q34528225-2ECA56E6-E4F1-4BB0-80B1-F0618DCBE884

P478

Q34528225-EBCFBF1B-6C28-4A5A-AA0F-1AEBBF1B9F69

P50

Q34528225-F324C81E-EF02-406A-9B31-F62696548E3D

P577

Q34528225-BC966DFA-FA83-4337-8BC3-98C0C443F637

P6179

Q34528225-36E1DE09-0CF7-4A50-BE1E-21BECD51C99D

P698

Q34528225-36226903-8D8F-4B82-853D-7F3F9EF96CEB

P932

Q34528225-5F69C860-652C-4E44-BBFD-5C916E739BB0

P356

P1433

P1476

Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy.

@en

P2093

Jianneng Li

http://www.w3.org/2001/XMLSchema#string

Kevin Rogacki

http://www.w3.org/2001/XMLSchema#string

Mohamed Abazeed

http://www.w3.org/2001/XMLSchema#string

Mohammad Alyamani

http://www.w3.org/2001/XMLSchema#string

Nima Sharifi

http://www.w3.org/2001/XMLSchema#string

Richard J Auchus

http://www.w3.org/2001/XMLSchema#string

Steven P Balk

http://www.w3.org/2001/XMLSchema#string

Sunil K Upadhyay

http://www.w3.org/2001/XMLSchema#string

Zhenfei Li

http://www.w3.org/2001/XMLSchema#string

P2860

Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival

Bioconductor: open software development for computational biology and bioinformatics

Expression cloning and characterization of oxidative 17beta- and 3alpha-hydroxysteroid dehydrogenases from rat and human prostate

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

LY191704: a selective, nonsteroidal inhibitor of human steroid 5 alpha-reductase type 1

Abiraterone in metastatic prostate cancer without previous chemotherapy

Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study.

Integrative clinical genomics of advanced prostate cancer.

HemI: a toolkit for illustrating heatmaps

PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes

P2888

P304

547-551

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NATURE17954

http://www.w3.org/2001/XMLSchema#string

P407

P433

7604

http://www.w3.org/2001/XMLSchema#string

P478

533

http://www.w3.org/2001/XMLSchema#string

P50

Mary-Ellen Taplin

P577

2016-05-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1030744978

http://www.w3.org/2001/XMLSchema#string

P698

27225130

http://www.w3.org/2001/XMLSchema#string

P932

5111629

http://www.w3.org/2001/XMLSchema#string